An Extension Study for Patients Previously Treated With ARQ 501

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Status and phase: Completed; Phase 2; Phase 1

Conditions: Cancer

Treatments: Drug: ARQ 501

Study type: Interventional

Funder types: Industry

Identifiers

NCT00622063

ARQ 501-115

Details and patient eligibility

About

To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed written informed consent
• Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment

Exclusion criteria

• Have not received previous treatment with ARQ 501 under a treatment protocol
• Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)